Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Neoadjuvant for TNBC
NCT04213898Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab in triple-negative breast cancer (TNBC), sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04213898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04213898.